, Volume 36, Issue 3, pp 321–323 | Cite as

Is the variation in the susceptibility of various species to atherosclerosis due to inborn differences in prostacyclin (PGI2) formation?

  • H. Sinzinger
  • P. Clopath
  • K. Silberbauer
  • M. Winter


Species exhibiting a higher susceptibility to the development of atherosclerosis have a reduced prostacyclin (PGI2)-generation in the arterial wall, which differs in various parts of the vascular system. As the difference in PGI2-formation in various diseases is a generalized vascular effect, the changes can be detected in all vessels. This is a very important point for diagnostic purposes in humans.


Atherosclerosis Arterial Wall Vascular System Prostacyclin Vascular Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 2.
    S. Moncada, R.J. Gryglewski, S. Bunting and J.R. Vane, Prostaglandins12, 715 (1976).CrossRefPubMedGoogle Scholar
  2. 3.
    A. Dembinska-Kiec, T. Gryglewska, A. Zmuda and R.J. Gryglewski, Prostaglandins14, 1025 (1977).CrossRefPubMedGoogle Scholar
  3. 4.
    A. Zmuda, A. Dembinska-Kiec, A. Chytkowski and R.J. Gryglewski, Prostaglandins14, 1035 (1977).CrossRefPubMedGoogle Scholar
  4. 5.
    R.J. Gryglewski, S. Bunting, S. Moncada, R.J. Flower and J.R. Vane, Prostaglandins12, 685 (1976).CrossRefPubMedGoogle Scholar
  5. 6.
    S. Moncada, J.R. Vane and B.J.R. Whittle, J. Physiol.273, 2 (1977).Google Scholar
  6. 7.
    T. Roberts and H. Strauss. Comparative Atherosclerosis, 1972.Google Scholar
  7. 8.
    K. Silberbauer, H. Sinzinger and M. Winter, Lancet1, 1356 (1978).CrossRefPubMedGoogle Scholar
  8. 9.
    S. Villa, A. Callioni and G. de Gaetano, Thromb. Res.11, 701 (1977).CrossRefPubMedGoogle Scholar
  9. 10.
    S. Moncada, E.A. Higgs and J.R. Vane. Lancet1, 18 (1977).CrossRefPubMedGoogle Scholar
  10. 11.
    R.A. Skidgel and M.F. Printz, Prostaglandins16, 1 (1978).CrossRefPubMedGoogle Scholar
  11. 12.
    S. Moncada, A.G. Herman, E.A. Higgs and J.R. Vane, Thromb. Res.12, 367 (1977).Google Scholar
  12. 13.
    A. Szczeklik, Int. Atherosclerosis Conf., Milan 1977.Google Scholar
  13. 14.
    H. Sinzinger, K. Silberbauer and M. Winter, VASA7, 350 (1978).PubMedGoogle Scholar
  14. 15.
    M. Okuma, Y. Yamori, K. Ohta and H. Uchino, Prostaglandins17, 1 (1979).CrossRefPubMedGoogle Scholar
  15. 16.
    G. Remuzzi, A.E. Cavenaghi, G. Mecca, M.B. Donati and G. de Gaetano, Lancet2, 1195 (1977).CrossRefPubMedGoogle Scholar
  16. 17.
    G. Schernthaner, K. Silberbauer, H. Sinzinger, H. Piza-Katzer and M. Winter, New Engl. J. Med.300, 366 (1979).Google Scholar
  17. 18.
    H. Sinzinger, K. Silberbauer, M. Winter and W. Auerswald, Lancet2, 840 (1978).CrossRefGoogle Scholar
  18. 19.
    H. Sinzinger, K. Silberbauer, O. Wagner, M. Winter and W. Auerswald, Atherogenese3, 123 (1978).Google Scholar
  19. 20.
    G.J. Dusting, S. Moncada and J.R. Vane, Prostaglandins13, 3 (1977).CrossRefPubMedGoogle Scholar
  20. 21.
    S. Moncada and J.R. Vane, in: Biochemical Aspects of Prostaglandins and Thromboxanes, p. 155. Ed. Paoletti. Academic Press, New York 1977.Google Scholar
  21. 22.
    G. Remuzzi, R. Misiani, D. Marchesi, M. Livio, G. Mecca, G. de Gaetano and M.B. Donati, Lancet1, 871 (1978).CrossRefGoogle Scholar
  22. 23.
    G. Remuzzi, M. Livio, R. Misiani, G. Mecca, G. de Gaetano and M.B. Donati, Atherogenese4 9 (1979).Google Scholar
  23. 24.
    H. Sinzinger, P. Clopath, K. Silberbauer and M. Winter, Artery5, 448 (1979).Google Scholar
  24. 25.
    S. Bunting, R.J. Gryglewski, S. Moncada and J.R. Vane, Prostaglandins12, 897 (1976).PubMedGoogle Scholar
  25. 26.
    A.G. Herman, S. Moncada and J.R. Vane, Arch. int. Pharm. Ther.227, 162 (1977).Google Scholar
  26. 27.
    G. Hornstra, E. Haddeman and J.A. Don, Thromb. Res.12, 367 (1978).CrossRefPubMedGoogle Scholar
  27. 28.
    S. Villa and G. de Gaetano, Prostaglandins14, 1117 (1977).Google Scholar
  28. 29.
    H.E. Harrison, A.H. Reece and M.J. Johnson, Life Sci.23, 351 (1978).CrossRefPubMedGoogle Scholar
  29. 30.
    C.R. Pace-Asciak and M.C. Carrara, Prostaglandins15, 704 (1978).CrossRefGoogle Scholar
  30. 31.
    C.R. Pace-Asciak, M.C. Carrara, G. Rangaraj and K.C. Nicolaou, Prostaglandins15, 1005 (1978).CrossRefPubMedGoogle Scholar
  31. 32.
    C.R. Pace-Asciak, M.C. Carrara and K.C. Nicolaou, Prostaglandins15, 999 (1978).CrossRefPubMedGoogle Scholar
  32. 33.
    R.A. Skidgel and M.F. Printz, Prostaglandins16, 1 (1978).CrossRefPubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1980

Authors and Affiliations

  • H. Sinzinger
    • 1
    • 2
    • 3
  • P. Clopath
    • 1
    • 2
    • 3
  • K. Silberbauer
    • 1
    • 2
    • 3
  • M. Winter
    • 1
    • 2
    • 3
  1. 1.Atherosclerosis Research Group at the Department of Medical PhysiologyVienna(Austria)
  2. 2.Pharma Research DivisionCiba-Geigy AGBasle(Switzerland)
  3. 3.2nd Department of Internal Medicine and 1st Department of SurgeryUniversity of ViennaVienna(Austria)

Personalised recommendations